Immune Dysregulation in HIV and COVID‐19 Co‐infection: Therapeutic Implications
Immunity, Inflammation and Disease · 2025
DOI: 10.1002/iid3.70164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2025. Verfasst von Maryam Nejabat und 4 weiteren Autor:innen. Beteiligte Einrichtung: HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: COVID-19, HIV Infections, SARS-CoV-2, Coinfection. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study is a part of Maryam Nejabat PhD thesis, under the supervision of Dr. M.M. Motamedifar, and was financially supported by Shiraz University of Medical…, Shiraz University of Medical Sciences.
Abstract (Originalsprache)
Background
Co‐infection with HIV and SARS‐CoV‐2 presents a complex clinical picture. Deciphering the immune response in this population, particularly the role of cytokines underlying immunopathogenesis could elucidates the development of targeted therapeutic interventions.
Methods
This prospective, two‐stage study enrolled 75 individuals with HIV diagnosed with COVID‐19 (case group) and 25 individuals from the general population infected with SARS‐CoV‐2 only (control group). COVID‐19 diagnosis followed World Health Organization guidelines. Plasma cytokine levels were measured using a cytokine bead array.
Results
The case group skewed slightly females (61.2% vs. 42.9% female in the control group) an average age of 3 years older (44.13 years vs. 40.86 years). Importantly, all the case group participants had mild complications, while a significant majority (88.1%) in the control group experienced severe complications. The control group displayed a substantially higher IgM titer 963 IU/mL compared to only 39.3 IU/mL in the case group. The control group had significantly higher levels of IL‐6, IL‐10, IFN‐γ, TNF‐α compared to the case group.
Conclusion
This study suggests a potentially distinct immune response in HIV‐positive patients when infected with SARS‐CoV‐2. Elucidating these differences could lead to the development of more effective treatment strategies for this vulnerable population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Bacteriology and Virology, Shiraz Medical School, Shiraz University Medical Science, Shiraz, Iran.
- Gastroenterohepathology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Shiraz HIV/AIDS Research Center (SHARC), Shiraz University of Medical Sciences, Shiraz, Iran.
ORCID-Profile: Maryam Nejabat, Mohammad Motamedifar, Saeid Amirizadeh Fard, Mohammadreza Heydari
Förderung
- This study is a part of Maryam Nejabat PhD thesis, under the supervision of Dr. M.M. Motamedifar, and was financially supported by Shiraz University of Medical…
- Shiraz University of Medical Sciences
Zitieren
APA
Nejabat, M., Motamedifar, M., Fard, S. A., Heydari, M., & Bemani, S. (2025). Immune Dysregulation in HIV and COVID‐19 Co‐infection: Therapeutic Implications. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70164
Vancouver
Nejabat M, Motamedifar M, Fard SA, Heydari M, Bemani S. Immune Dysregulation in HIV and COVID‐19 Co‐infection: Therapeutic Implications. Immunity, Inflammation and Disease. 2025. doi:10.1002/iid3.70164
BibTeX
@article{Nejabat2025,
author = {Nejabat, Maryam and Motamedifar, Mohammad and Fard, Saeid Amirizadeh and Heydari, Mohammadreza and Bemani, Soudabeh},
title = {Immune Dysregulation in HIV and COVID‐19 Co‐infection: Therapeutic Implications},
journal = {Immunity, Inflammation and Disease},
year = {2025},
doi = {10.1002/iid3.70164}
}
EUVIMED